Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

ubs-maintains-neutral-on-dave-inc-(dave)-march-13,-2026

UBS Maintains Neutral on Dave Inc (DAVE) March 13, 2026

Mar 13, 2026

On March 13, 2026 UBS maintained a Neutral view on Dave Inc. (DAVE), leaving the DAVE analyst rating…

Read more
ocugen-stock-surges-amid-positive-analyst-coverage-and-clinical-progress

Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress

Mar 13, 2026

Ocugen, Inc. stocks have been trading up by 5.77 percent amid promising FDA approvals boost investor confidence. Key…

Read more
morgan-stanley-maintains-overweight-on-sana-biotechnology,-inc.-(sana)-march-2026

Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026

Mar 13, 2026

Morgan Stanley maintained an Overweight rating on Sana Biotechnology, Inc. (SANA) on March 13, 2026. The firm called…

Read more
dollar-general-stock-(dg)-gets-mixed-signals-from-analysts-after-earnings

Dollar General Stock (DG) Gets Mixed Signals from Analysts After Earnings

Mar 13, 2026

Dollar General stock fell on Friday alongside mixed analyst coverage following the company’s latest earnings report.

Read more
this-karman-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-friday-–-genasys-(nasdaq:gnss),-h2o-america-(nasdaq:hto)

This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday – Genasys (NASDAQ:GNSS), H2O America (NASDAQ:HTO)

Mar 13, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
cantor-fitzgerald-keeps-overweight-on-agios-pharmaceuticals,-inc.-(agio)-mar-2026

Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026

Mar 13, 2026

Cantor Fitzgerald on March 12, 2026 maintained an Overweight rating on Agios Pharmaceuticals, Inc. (AGIO). The headline AGIO…

Read more
cantor-fitzgerald-maintains-overweight-on-cmpx-(compass-therapeutics,-inc.),-mar-2026

Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026

Mar 13, 2026

Cantor Fitzgerald on March 12, 2026 maintained an Overweight stance on Compass Therapeutics, Inc. (CMPX), the headline CMPX…

Read more
new-analyst-optimism-and-insider-sale-might-change-the-case-for-investing-in-rush-street-interactive-(rsi)

New Analyst Optimism and Insider Sale Might Change The Case For Investing In Rush Street Interactive (RSI)

Mar 13, 2026

Recently, Freedom Capital Markets initiated coverage of Rush Street Interactive with a Buy rating, following quarterly results that…

Read more
benchmark-maintains-buy-on-rivian-automotive,-inc.-(rivn)-march-12,-2026

Benchmark Maintains Buy on Rivian Automotive, Inc. (RIVN) March 12, 2026

Mar 13, 2026

Benchmark maintained a Buy rating on Rivian Automotive, Inc. (RIVN) on March 12, 2026 following the company’s R2…

Read more
latest-us-analyst-ratings:-march-12th,-2026

Latest US Analyst Ratings: March 12th, 2026

Mar 13, 2026

Analyst Ratings (USA) Today’s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities…

Read more
wolfe-research-maintains-outperform-on-celcuity-inc-(celc)-mar-12,-2026

Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026

Mar 13, 2026

Wolfe Research maintained an Outperform rating on Celcuity Inc (CELC) on March 12, 2026 at 09:58 AM, keeping…

Read more
latest-us-analyst-ratings:-march-12th,-2026

Latest US Analyst Ratings: March 12th, 2026

Mar 13, 2026

Analyst Ratings (USA) Today’s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 6
  6. 7
  7. 8
  8. 9
  9. 10
  10. 11
  11. 12
  12. ...
  13. 377
  14. »

Posts pagination

Newer posts Page 1 … Page 9 … Page 377 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.